Hoxton Planning & Management LLC Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Hoxton Planning & Management LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,880 shares of the biopharmaceutical company’s stock after buying an additional 480 shares during the quarter. Hoxton Planning & Management LLC’s holdings in Gilead Sciences were worth $325,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Brookstone Capital Management raised its position in shares of Gilead Sciences by 0.7% in the 3rd quarter. Brookstone Capital Management now owns 146,852 shares of the biopharmaceutical company’s stock worth $12,312,000 after buying an additional 992 shares during the period. FCF Advisors LLC raised its position in Gilead Sciences by 8.4% in the third quarter. FCF Advisors LLC now owns 75,469 shares of the biopharmaceutical company’s stock valued at $6,327,000 after purchasing an additional 5,837 shares during the period. Atomi Financial Group Inc. raised its position in Gilead Sciences by 36.0% in the third quarter. Atomi Financial Group Inc. now owns 6,081 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 1,610 shares during the period. Park Place Capital Corp raised its position in Gilead Sciences by 25.3% in the third quarter. Park Place Capital Corp now owns 8,431 shares of the biopharmaceutical company’s stock valued at $707,000 after purchasing an additional 1,705 shares during the period. Finally, Aprio Wealth Management LLC purchased a new position in Gilead Sciences in the third quarter valued at about $290,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Barclays raised their price objective on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research report on Monday. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Finally, BMO Capital Markets raised their target price on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $83.94.

Gilead Sciences Stock Up 0.9 %

NASDAQ:GILD opened at $85.21 on Wednesday. The company has a market capitalization of $106.16 billion, a price-to-earnings ratio of 236.69, a price-to-earnings-growth ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The stock has a 50-day simple moving average of $79.20 and a 200 day simple moving average of $71.98. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Sell-side analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.61%. The ex-dividend date of this dividend was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.